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Abstract
Background: Pulmonary arterial hypertension (PAH) is an uncommon condition with progressive heart failure and
premature death. Treatment costs up to £120,000 per patient per year, and the psychological burden of PAH is
substantial. Mindfulness-based stress reduction (MBSR) is an intervention with the potential to reduce this burden,
but to date, it has not been applied to people with pulmonary hypertension. We wished to determine whether a
trial of MBSR for people with PAH would be feasible.
Methods: A customised gentle MBSR programme of eight sessions was developed for people with physical
disability due to PAH, and they were randomised to group-based MBSR or treatment as usual. The completeness
of outcome measures including Beck Anxiety Index, Beck Depression Inventory and standard physical assessment
at 3 months after randomisation were recorded. Health care utilisation was measured. Attendance at the sessions
and the costs involved in delivering the intervention were assessed. Semi-structured interviews were conducted
to explore the acceptability of the MBSR intervention and when appropriate the reasons for trial non-participation.
Results: Fifty-two patients were recruited, but only 34 were randomised due to patients finding it difficult to travel to
sessions. Twenty-two completed all questionnaires and attended all clinics, both routine and additional in order to
collect outcomes measures. The MSBR sessions were delivered in Bristol, Cardiff and London, costing, on average,
between £2234 (Cardiff) and £4128 (London) per patient to deliver. Attendance at each session averaged between
two patients in Bristol and Cardiff and three in London. For those receiving treatment as usual, clinician blinding was
achievable. Interviews revealed that people who attended MBSR found it interesting and helpful in managing their
symptoms and minimising the psychological component of their disease.
Conclusions: We found that attendance at group MBSR was poor in people with chronic PAH within the context of a
trial. Achieving better MBSR intervention attendance or use of an Internet-based programme might maximise the
benefit of MBSR.
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Background
Pulmonary arterial hypertension (PAH) is an unpredict-
able and life-limiting condition. It results in progressive
increases in pulmonary vascular resistance, ultimately
leading to right ventricle failure and premature death
[1]. It is characterised by debilitating progressive symp-
toms of severe breathlessness, fatigue, cyanosis and
haemoptysis and declining functional ability. Precise
national prevalence data are unconfirmed, but 5538
patients are monitored in the UK (Dr. L Howard per-
sonal communication from National Audit of PAH,
2010), and the number is rising with increasing
awareness.
The causes of PAH range from those with idio-
pathic PAH (IPAH), with a short life expectancy of 2.
8 years without treatment [2], to those associated
with congenital heart disease (APAH), who commonly
live into their fourth decade for whom treatment re-
mains palliative [3]. Treatment can be invasive, pain-
ful and upsetting, and it is not clear whether new
methods of treatment have increased life expectancy
[3]. Most patients are seen in clinic at least twice a
year and may require hospital admission to initiate
treatment. Care costs are up to £120,000 per person
per year [4]. Supporting patients as they cope with
the psychological distress associated with PAH is an
important adjunct of care. Living with an unpredict-
able future, complex treatments and lifestyle changes
means that the emotional burden of PAH is substan-
tial [5].
Pulmonary hypertension and psychological health
The symptoms of PAH can have a devastating impact
on daily life. Many people cannot work and have lim-
ited mobility and independence, and women are ad-
vised to avoid pregnancy [6]. They may have
consistently high levels of anxiety (20%), depression
(26%) and panic (25%) [7], associated with decreased
quality of life and physical functioning [8], as well as
an increase in concern about symptoms [5, 9, 10].
Worryingly, only 24.1% of patients reported seeking
professional help for psychological effects [7]. Anxiety
both exacerbates and mimics symptoms of PAH mak-
ing it difficult for patients to interpret their symptoms
and increasing their need for support. For example,
breathlessness and chest pain are features of anxiety
but also of PAH. Qualitative analysis from research
with PAH patients revealed that they consciously
‘hold back’ in order to avoid provoking symptoms
and increased anxiety due to a heightened sense of
awareness as they approached each activity, for fear
of not being able to catch their breath [11]. Anxiety
may also stem from the uncertainties associated with
prognosis, treatment and course of the illness [12].
Mindfulness-based stress reduction intervention
Mindfulness is defined as ‘the awareness that emerges
through paying attention on purpose, in the present mo-
ment, and non-judgmentally to the unfolding of experi-
ence moment by moment.’ [13]. Mindfulness-based
stress reduction (MBSR) is a group-based course that
runs for a recommended eight weekly sessions and
includes education about stress and its effects on the
body, becoming aware of unhelpful attitudes and think-
ing patterns, defining mindfulness and using it in every-
day life, formal meditation techniques and gentle
stretching. Participants are given a resource booklet to
accompany the course and asked to continue practising
what they have learnt at home. Benefits include in-
creased ability to cope, improvements in mental health,
physical functioning, well-being, quality of life, decreased
psychological distress, enhanced functional status and
reduced physical symptoms for people with chronic
pain, cancer, heart disease, depression, anxiety, fibro-
myalgia, rheumatoid arthritis, type 2 diabetes and
chronic fatigue [14–16]. Positive results have been dem-
onstrated for continued practice and maintained effect
after 6 months [17, 18]. Significant effects have been ob-
served with eight (2.5-h) weekly sessions of MBSR on
blood pressure [19], vascular disease [20], lifestyle stress,
blood pressure [21] and general cardiovascular diseases
[22]. To date, there has been no intervention for people
with pulmonary hypertension.
Aims and objectives
The overall aim of this study was to assess the feasibility
and pilot the methods of a randomised controlled trial
comparing MBSR with treatment as usual. This would
examine the clinical and cost-effectiveness of an MBSR
intervention for people with PAH aged over 16. The
pilot study reported here mirrored as closely as possible
the intended design and conduct of a larger trial, so that
the information it provided could be used to inform the
design of that trial.
The specific objectives of the pilot study were to:
1. Assess the processes of participant identification,
recruitment, randomisation and collection of
outcome data, including rates of recruitment,
attrition, questionnaire completion and overall
follow-up. Assess logistics, in particular how to
deliver a group-based intervention in a number
of geographical locations.
2. Assess acceptability to participants of the protocol,
including receiving the intervention, being in the
control group and remaining in the study for
15 months.
3. Develop and test data collection methods, including
outcomes and resource use.
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4. Obtain descriptive distributional data on the
outcome measures for this population, including
measures of spread, to inform sample size
calculation.
5. Estimate the cost of delivering the MBSR
intervention, exploring different settings and group
size.
Methods
Participants
We included those patients with a clinical diagnosis of
PAH who were aged 16 years or older (due to the need
for participants to self-reflect and participate in a group
of mixed ages) and who were deemed physically and
psychologically stable enough to participate in a study
for approximately 15 months by their care team. We
excluded those with significant learning disabilities and
who lacked capacity to consent or who were not fluent
in English. In addition, we excluded those who were un-
able to take part (e.g. prior commitments, excess travel)
or who were involved in simultaneous research projects.
We planned to randomise 42 participants into the
pilot study in a 1:1 ratio. The group size was intended to
be seven participants. We wished to have three groups
in each of the randomised intervention or treatment as
usual cohorts. This suggested a total of 42 participants
and would allow for some dropout during the study.
The research assistant approached potentially eligible
participants with information about the trial following a
routine clinic visit. Initial recruitment was at a single
site, Bristol, which included patients from a wide catch-
ment area, including South Wales and South West
England. If they were interested in participating, full
information about the trial was provided, and partici-
pants were given the opportunity to ask questions. If the
participant wished to proceed, written informed consent
was sought along with the completion of baseline ques-
tionnaires. To avoid lengthy travel times, intervention
groups were arranged in various outlying locations. We
aimed for a minimum of seven participants per interven-
tion group, necessitating recruitment of at least 14
participants within a geographical area from which par-
ticipants were happy to attend a central site to receive
the intervention (if so randomised). MBSR sessions were
offered in the early afternoon from 12 to 2 pm, through-
out the year. Baseline measures were collected, and once
there were sufficient patients, the intention was to ran-
domise on a 1:1 basis to intervention or control.
It took 18 months to recruit 18 participants in the
Bristol centre. It became apparent that it would not be
possible to undertake randomisation as intended, due to
potential participants living in widely dispersed areas
making attendance at weekly group sessions difficult.
We then over recruited (with ethics committee approval)
patients to a waiting list of potential participants living
near two geographic locations (Bristol and Cardiff ) who
were not randomised until the group size at that site be-
came large enough. We also expanded the recruitment
to an additional site. This additional site, Hammersmith
Hospital, is a National Specialist Pulmonary Hyperten-
sion Centre that manages 1200 people with pulmonary
hypertension. The majority of the patients lived within a
2-hour radius, but some travelled to the centre from
across the UK. Only those close to London were in-
cluded from this site for ease of travelling to the MBSR
sessions. Due to low numbers, the randomisation ratio
was also increased to ensure a viable number of patients
could be recruited to form MBSR groups of sufficient
size (up to a maximum of 3:1). Additionally, we rando-
mised (with ethics committee approval) a smaller group
of seven participants with the additional members of the
MBSR group made up from patients from the same
clinic but with different diagnoses.
Participants were informed of their allocation by letter
along with details of venue and timings for the MBSR
group sessions. After baseline (T1), follow-up was
planned for 10–12 weeks (T2), 6 months (T3) and
15 months (T4) after randomisation. All patients were
followed up to 6 months. However, as recruitment took
much longer than originally planned, only patients (n =
18) from the Bristol centre were followed for the add-
itional time point of 15 months post-randomisation. For
this reason, in our analysis, we focussed on 6-month
outcomes.
Acceptability of the intervention
Adaptations to the MBSR programme were based on ad-
vice and material given by Michael Speca (personal com-
munications 20 October 2010 to 22 February 2011) and the
experiences of patients. Prior to the pilot study, we invited
four patients to undergo baseline assessment, attend the 8-
week intervention and have an assessment at follow-up.
Based on this, we further tailored the MBSR programme to
patients with PAH.
An experienced clinical psychologist and assistant psych-
ologist delivered the course in a group setting in eight 2-
hour weekly sessions. The intended group size was seven
participants. The first session explained about MBSR and
its role in promoting health. The other sessions were learn-
ing and practising stretching exercises and breathing exer-
cises designed to reduce stress. Each group received their
intervention at a location near to their home. Treatment as
usual consisted of attendance at clinics and telephone sup-
port by the pulmonary hypertension nurses or doctors.
Test data collection and patient-centred outcomes
Outcomes included physiological measures and self-
report questionnaire assessment at baseline, 10–12 weeks
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and 6- and 15-month post-randomisation. These timings
were chosen to provide long-term outcome data but also
to coincide with usual outpatient clinics to avoid add-
itional burden for participants. We conducted semi-
structured interviews after the 15-month time-point with
participants from both arms of the trial to determine the
acceptability of participation and elicit perceptions of the
MBSR the intervention from participants in this group.
We did not specify a primary outcome for the pilot
trial; outcomes measured included the following:
1. Symptoms of anxiety and depression—measured
respectively by the Beck Anxiety Index (BAI) and
Beck Depression Index (BDI) [23, 24].
2. Measures of physical functioning—as assessed by
echocardiogram, electrocardiogram, New York
Heart Association (NYHA) functional class and
6-min walk test
3. Measure of health and social care resource use.
4. Health-related quality of life—measured by the
components of the SF36 questionnaire [25].
The study was not powered to identify clinically im-
portant differences between MBSR and treatment as
usual but aimed to determine response rates and
whether a future trial would be possible.
Self-report questionnaires included a demographic
sheet recording patients’ age, gender, ethnic origin and
work status; BAI [23]; BDI [24]; SF-36 [25] and a
patient-completed resource use questionnaire (RUQ):
asking patients about their use of secondary, primary
and community health care. The SF36 measures health-
related quality of life on eight dimensions and two sum-
mary scores: physical and mental health [25]. All SF36
measures used norm-based scoring with population
means of 50. A subset of SF-36 questions can also be
used to estimate a single preference-based utility score
anchored at 1 (best health) and 0 (health state as bad as
death) [25, 26]. It is appreciated that the PCS and MCS
components are validated against an American popula-
tion and would need to be validated for this sick popula-
tion before being suitable for interpretation if a full trial
was to follow.
Physiological measures were collected as part of the
routine clinical appointment by nursing and medical and
technical staff as usual. Such physiological outcomes (e.
g. echocardiogram, electrocardiogram, functional class,
6-min walk test) were collected but are not reported in
this paper, which discusses the feasibility of a rando-
mised controlled trial (RCT).
Session record forms
Therapists delivering MBSR completed session record
forms that included staff grade and time to prepare,
travel to and deliver the sessions, assistant’s time if re-
quired, equipment and materials used during the ses-
sion, duration of the session, number of patients
expected to attend and actually attending the session
and room hire costs.
Blinding and measures taken to avoid bias
The PAH specialist clinical team was blinded to the
treatment arm, and the statistical analysis was intended
to be conducted without knowledge of patient allocation
(except for health resource utilisation). Compliance with
the intervention was recorded by attendance at the
intervention and a diary for the set home tasks. Partici-
pants were withdrawn from the intervention if their care
team identified that they were too ill to continue, or if
the participant opted to discontinue attendance at
sessions.
Descriptive data and outcomes
The format and analysis for this study followed the
extension of the CONSORT principles for pilot trials
[27]. Participant data are presented as appropriate for
a pilot study, giving numbers of those patients identi-
fied, contacted, indicating potential interest, subse-
quently found to be ineligible, recruited and those
completing outcome measures at each stage. Descrip-
tive statistics are presented on the outcome measures.
Formal comparative analyses between arms were not
undertaken.
Data from the semi-structured interviews were tran-
scribed verbatim and analysed using inductive content
analysis techniques. Words, phrases, poignant passages
or concepts were assigned codes, grouped together and
reduced to key themes and sub-categories to represent a
holistic interpretation of the patient experience.
Valuing and analysing resources required to deliver the
intervention
MBSR was delivered by a clinical psychologist (band
8a), with assistance from a hospital clinical support
worker (band 2), and valued using unit costs for
health and social care tariffs [28]. The therapist deliv-
ering MBSR in London was privately hired and
charged a set fee for session delivery. We used local
estimates for room hire costs and recorded actual ex-
penses for therapy materials (e.g. yoga mats, blankets,
blocks and meditation bells).
The intervention was delivered in different settings for each
trial centre. We assumed an opportunity cost of zero for Bris-
tol where a hospital room was available to deliver the MBSR
sessions. In Cardiff, the intervention was delivered at a local
community centre at discounted room hire costs. London
used a conference centre with a discounted room hire cost.
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Results
Participants
Of the 181 patients attending the Bristol clinic, 71 were
eligible (Fig. 1). Reasons for ineligibility included learn-
ing difficulties, young age and absence of PAH. Of the
71, 36 declined participation: 12 due to living too far
away, 1 could not manage the time of the interventions,
2 had transport issues and 21 declined for other reasons.
Eighteen of the 35 consented were randomised. Of those
not randomised, 14 were waiting for a large enough
group size in their area, 2 withdrew whilst waiting for
randomisation and 1 was discharged to another clinic
whilst waiting to be randomised. Four patients with pul-
monary hypertension following the Fontan operation
were included since their symptoms and treatment are
very similar to those with pulmonary arterial hyperten-
sion. This operation is performed to palliate those
patients with only one functioning ventricle.
Fig. 1 Consort diagram
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Acceptability of the intervention
Of the 1343 patients attending the clinic at the second
recruitment centre, Hammersmith, London, 748 patients
were considered ineligible as they lived too far away to
travel to a weekly intervention. This left 595 potentially
eligible patients for screening. Reasons for ineligibility
included new patients not yet seen in clinic (n = 5), too
young (n = 26), learning difficulties (n = 7), did not have
PAH (n = 203), died before study commenced (n = 5),
failed to attend (n = 1), poor English (n = 35), no reason
offered (n = 185) and discharged before the study began
(n = 58).
The consent forms for the remaining 78 patients were
posted, of which 41 were not returned; 20 declined due
to geographical location (n = 2), the time of the interven-
tions (n = 1) and transport issues (n = 1); and 16 declined
to take part. Hence, 17 were randomised, but 1 was ex-
cluded after randomisation as they were already enrolled
in another trial.
Feasibility of data collection
The feasibility outcomes are described in Table 1.
All those consented to take part and who filled in
questionnaires had baseline physical assessment data.
One consented and randomised patient died after con-
sent before data could be collected.
Of those 52 consented, only 34 were randomised to
groups. This was because it was not possible to find
enough patients in a certain geographical area to make
group intervention possible.
Only 19 of 34 randomised completed all the ques-
tionnaires, but 45% (24/52) of patients initially re-
cruited completed questionnaires at the 6 months
follow-up. Comparison of baseline characteristics
(Table 2) between those who were and were not ran-
domised suggest that those who were randomised
might be more likely to be female, not working, to
have retired due to ill health, practice yoga and from
the London site. The purpose of the table is therefore
to show the characteristics between those who were
randomised and those who were not, rather than to
show outcome results, this not being the purpose of
the study.
The protocol was found to be acceptable to many of
the participants. However, as seen in the consort dia-
gram, there was a steady attrition rate, partly due to ill
health, such that only 55% were able to complete the
MBSR programme. Blinding of research analysts was
achieved. The fact that completion of outcome measures
was incomplete might be due to the fact that patients
who have limited physical mobility found it difficult to
attend sessions.
Table 3 demonstrates the completeness of the data in
order to inform a possible future trial using the same
methodology. It is of note that the denominator at T4 is
only 7 since the patients randomised at the London
centre were not followed long enough to achieve this
time point.
Figures 2 and 3 demonstrate that we were able to
show different components of the SF36, based on the
data that we received. The labelling has deliberately been
left obscure (as arm A and arm B) since the study was
not powered to determine a difference between the two
arms of intervention or treatment as usual. It was
important that neither ourselves nor others were inad-
vertently trying to determine an effectiveness of the
intervention since this was not the aim of the study.
Feasibility outcomes, patient-centred outcomes and
descriptive measures
The outcomes are described in Table 1.
Feasibility testing was completed by the four pa-
tients who reported finding the MBSR course highly
beneficial: ‘I go out a lot more since the Mindfulness
course and I am significantly more involved in what I
can contribute to our day to day lives rather than sit-
ting on the side lines, both physically and mentally.
Mindfulness has moved me from being defensive and
on the back foot most of the time to being far more
positive to demands that are made of me and in
Table 1 Feasibility outcomes
Trial feasibility measure—proportion of… Percentage (n/total N) 95% confidence interval
Patients screened as eligible (Bristol) 39.2% (71/181) [32.1, 46.7]
Patients screened as eligible (London) 13.1% (78/595) [10.5, 16.1]
Eligible patients consented 34.9% (52/149) [27.2, 43.1]
Consented participants randomised 65.4% (34/52) [50.9, 78.0]
Randomised participants with baseline questionnaire data 91.2% (31/34) [76.3, 98.1]
Randomised participants with 3-month questionnaires 67.6% (23/34) [49.5, 82.6]
Surviving randomised participants with 6-month questionnaires 55.9% (19/34) [37.9, 72.8]
Group 1 participants with 15-month questionnaires 55.5% (5/9) [21.2, 86.3]
Participants with baseline, 3- and 6-month questionnaire data 55.9% (19/34) [37.9, 72.8]
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Table 2 Baseline characteristics and health-related quality of life comparison between those recruited and randomised and
those recruited but not randomised (percentages, absolute ratios and mean and standard deviations)
Variable Randomised Not randomised Total sample
Sex (% male) 20.5% (7/34) 52.9% (9/17) 31.4% (16/52)
Age (mean (min, max)) 50.0 (22, 76) 53.7 (20, 88) 51.3 (20, 88)
Ethnic origin (% white British) 87.1% (27/31) 100% (17/17) 91.7% (44/48)
Currently working 32.3% (10/31) 41.2% (7/17) 35.4% (17/48)
Stopped working due to ill health? 32.2% (10/31) 23.5% (4/17) 29.1% (14/48)
Retired 31.0% (9/29) 35.3% (6/17) 32.6% (15/46)
Practice yoga regularly 9.7% (3/31) 0% (0/17) 6.3% (2/48)
Regularly meditate 9.7% (3/31) 5.9% (1/17) 8.3% (4/48)
From the primary clinic 27.3% (9/34) 100% (18/18) 51.9% (27/52)
SF-36 PCS 37.9 (11.8) 37.0 (12.0) 37.6 (11.8)
SF-36 MCS 43.4 (11.7) 48.8 (7.9) 45.3 (10.7)
SF-6D 0.632 (0.131) 0.639 (0.099) 0.634 (0.119)
Anxiety (BAI) 14.5 (11.6) 10.5 (7.3) 13.1 (10.3)
Depression (BDI) 17.3 (12.6) 10.7 (7.0) 15.1 (11.4)
The higher scores in BAI and BDI imply increased reported symptoms. BAI range was from 6 to 42, and for BDI, the range was 2–27 across both groups. The
individual scores were deliberately not reported so as to avoid unintentional interpretation. There was no cut-off in the values
Table 3 The number (percentage) of randomised patients with usable data at the four time points
Variable T1 (baseline) T2 (2–4 weeks) T3 (6 months) T4 (15 months)
Date of diagnosis 17 (50%) 23 (67.65%) 18 (52.94%) 7 (77.78%)
Diagnosis 32 (94.12%) 25 (73.53%) 21 (61.76%) 7 (77.78%)
Life expectancy from now 15 (44.12%) 8 (23.53%) 9 (26.47%) 1 (11.11%)
Date of last clinic visit 26 (76.47%) 23 (67.65%) 21 (61.76%) 6 (66.67%)
Current medication 32 (94.12%) 25 (73.53%) 21 (61.76%) 7 (77.78%)
Change in symptoms 31 (91.18%) 23 (67.65%) 16 (47.06%) 6 (66.67%)
What NYHA functional class is the patient now in 32 (94.12%) 24 (70.59%) 20 (58.82%) 7 (77.78%)
Number who changed to functional class since last visit 29 (85.29%) 23 (67.65%) 19 (55.88%) 6 (66.67%)
Patient’s medication has changed since last visit? 29 (85.29%) 25 (73.53%) 20 (58.82%) 7 (77.78%)
Change given (of those who changed medication) 4 (100%) 8 (88.89%) 9 (100%)
Reasons given (of those who changed medication) 3 (75%) 8 (88.89%) 8 (88.89%)
Opinion of whether patient is better, the same or worse 21 (61.76%) 19 (55.88%) 16 (47.06%) 4 (44.44%)
6-min walk 19 (55.8%) 12 (35.3%) 14 (41.1%) 4
Echocardiogram 19 (55.8%) 15 (44.1%) 13 (38.2%) 3
ECG 16 (47.1%) 14 (41.1%) 15 (44.1%) 4
SF-36 score
SF-36 PCS 91.2% (31/34) 67.6% (23/34) 52.9% (18/34) 77.8% (7/9)
SF-36 MCS 91.2% (31/34) 67.6% (23/34) 55.9% (19/34) 77.8% (7/9)
SF-6D 88.2% (30/34) 67.6% (23/34) 52.9% (18/34) 66.7% (6/9)
BAI 85.3% (29/34) 67.6% (23/34) 61.9% (21/34) 77.8% (7/9)
BDI 91.2% (31/34) 67.6% (23/34) 58.8% (20/34) 77.8% (7/9)
Tulloh et al. Pilot and Feasibility Studies  (2018) 4:78 Page 7 of 11
many ways more pro-active. In a very real sense
Mindfulness together with the medication is allowing
me to reoccupy areas of my life I have retreated from
and take on new things.’
In addition, we undertook 13 semi-structured inter-
views (control and five intervention patients) that
gave us feedback on the acceptability of the protocol.
Those who did attend the MBSR sessions found them
useful, interesting and helpful in managing their
symptoms and minimising the anxiety and psycho-
somatic symptoms. This has informed us of several
key themes: (1) wanting to help, (2) challenges with
Fig. 2 Graphical representation of the outcome data for mental component score of SF36 (time points 1 to 3 only, and only participants with
data at all three time points)
Fig. 3 Graphical representation of the outcome data for the physical component score of the SF36 (time points 1 to 3 only, and only participants
with data at all three time points)
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questionnaire completion, (3) preferred time of year
and (4) taking part again.
Theme 1: Wanting to help
Six participants identified a sense of being indebted, wanting
to help or ‘give something back’.
Truly, totally wonderful people there… They just say
‘would you like to take part in a survey’ and I just say ‘yes
I will’ ….. I had no idea what on earth I was signing up
for. 1119, female, age 69.
I was asked if I wanted to do it and I’m one of those
people…where they always ask me - yeah, alright, you’ve
got me, use me type of thing. So I was like yeah, I don’t
mind. 1123, female, age 53.
I was happy to go ahead if it helps. 1026, male, age 39.
Theme 2: Challenges with questionnaire completion
Many found the psychological questionnaires quite long and
repetitive, which possibly influenced how individuals
approached answering them.
There seemed to be quite a lot of questions although
fairly quick to complete. 1112, female, age 55.
I thought some of them were a bit long and maybe
very repetitive….It didn’t take too long – about half
an hour to three quarters of an hour. 1123, female,
age 53.
I found the questionnaires quite straightforward.
There was one of the questionnaires that I always
found a little bit difficult from the point of view that
the questions were very leading….There was no room
for manoeuvre,,, it was either sort of trying to draw
you to the conclusion that you were quite depressed
or not at all depressed, there was no middle road…..so
it felt a little bit, sort of contrived almost. 1011, male,
age 43.
Theme 3: Preferred time of year and time of day of
intervention
In the winter, the darker evening and cold weather were
seen as quite detrimental to participation, but there were
varied opinions around the time of day.
I mean, I understand it had to be that time of day but
the thing was it was winter so it was dark ….. and wet
and cold…. I think that would have put people off. If
it had been earlier in the day or in the Spring or
Summer, I think you would’ve got a lot more people
to go. 1070, female, age 41.
I think, although I had to get up earlier, it was a good
time of day to get up because it means you have the
rest of the day. 1127, female, age 63.
Theme 4: Taking part again
Seven of the 13 interviewees expressed a willingness to
take part either in the study as a whole or the interven-
tion again if asked.
Yes, I don’t mind doing it again if it helps. 1079, male,
age 68.
It was a good experience and I wish I could go
regularly. 1070, female, age 41.
I quite enjoyed it and I would do it again if you asked
me. 1125, female, age 61.
Nothing really worried me one way or the other. I’d
do it again. 1026, male, age 39.
Participants report that they found the MBSR tech-
niques helpful in assisting with management of their
symptoms and have continued to use them many
months after the study period finished.
Cost of delivering MBSR
The average cost of delivering the eight MBSR sessions
was similar in Bristol and Cardiff, £2234 (SD £286) and
£2423 (SD £295), respectively, but higher in London
£4128 (SD £270) (Table 4). Higher costs in London re-
flect the private therapist fee and higher room hire costs
(between £160 and £260 per room, compared to £15 per
room at the local community centre in Cardiff ).
The cost of the intervention is highly sensitive to the
number of patients attending the sessions. Although we
invited seven patients to attend each group, actual
attendance averaged one to two (Bristol), two (Cardiff )
and two to three (London) patients. Therefore, the aver-
age cost per patient attending MBSR in the trial was
high and ranged from £1211 in Cardiff to £1538 in
London.
Discussion
This study provides insight into the difficulty of recruit-
ing to a group-based intervention study in a rare disease.
Many of the patients found the therapy helpful, but it is
not yet possible to determine its benefit. There are
significant barriers to implementing face-to-face group
therapies in rare diseases with geographically dispersed
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patients. Research on these interventions is difficult as
numbers are constrained. For those who were clinically
stable and had little limitation, demands of professional
employment often prevented travel to intervention dur-
ing working hours. For those who were unwell, it was
too much of an imposition to travel to the sessions,
especially in the winter months.
The work of Bauer-Wu has attempted to address this
concern that sick patients may be too unwell to travel to
group mindfulness sessions. Bauer-Wu undertook one-
on-one sessions for 17 min on a daily basis with those
undergoing stem cell transplantation. 78.9% completed
the interventions, considerably more than in the present
study [29]. Others have tried undertaking the MBSR
programmes over six telephone conversations [30] or
even undertaking the whole programme in a single ses-
sion, based on the acceptance and commitment model
[31]. These models show that there may be other
methods of delivering mindfulness, although the valid-
ation of their effectiveness is still rather lacking in the
longer term, perhaps requiring increased re-
enforcement. In light of the chronic ill health of our pa-
tients with PAH and the fact that it is a relatively rare
disease, such alternatives might offer better means of de-
livering the intervention.
Due to the wish to recruit sufficient people for the
expected size of intervention groups, we tested out the
approach of topping up the group numbers with patients
with similar clinical diagnoses. This was found to be a
useful and feasible way of randomising at a site with low
patient numbers. We would recommend this method to
others attempting recruitment to group interventions. It
is not clear whether the MBSR programme which is tai-
lored for people with PAH would be less appropriate for
those with similar diagnoses or whether the inclusion of
people without PAH might reduce the efficacy of the tai-
lored intervention for those with the disease.
MBSR however does appeal to a significant proportion
of this patient population. The semi-structured inter-
views revealed that those who attended were pleasantly
surprised by the effect of MBSR and continued to prac-
tise many months later. It is possible that a more suc-
cessful intervention would use the same techniques
remotely, via e-health devices such as a smartphone app
or a web or video-based programme or combination of
these. Some studies using Internet-based MBSR pro-
grammes have already been introduced [32]. This would
allow the benefit for the patients without the need for
travel to group meetings. Those who found the timing of
the meetings restrictive due to work or other commit-
ments would be able to take part when suitable. Achiev-
ing better MBSR attendance is very important in order
to maximise the potential benefit of MBSR and make it
more likely to be cost-effective for the NHS. Larger
groups (e.g up to 12 patients) might be preferable but
will be difficult to achieve for a rare disease like PAH.
Conclusion
It is clear that the methodology of this pilot trial will not
translate more generally to other rare diseases in its
current form. However, we have devised a suitable MBSR
programme, which may be of benefit in PAH, a debilitat-
ing and uncommon disease. This study highlights the
potential benefits of MBSR for patients with rare diseases
whilst drawing attention to the significant challenges
posed in delivering robust evaluations of group-based
MBSR in these populations. It is possible that future re-
search could use the same methodology but would need
to be delivered in a way to accommodate at home use as
travel was the main factor which prevented participation.
This might be by an “e” programme delivered online or by
some other telephone or single visit method—as others
have tried.
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